Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.
Wobma H, Kapadia M, Kim HT, Alvarez-Calderon F, Baumeister SHC, Duncan C, Forrest S, Gorfinkel L, Huang J, Lehmann LE, Li H, Schwartz M, Koreth J, Ritz J, Kean LS, Whangbo JS.
Wobma H, et al. Among authors: lehmann le.
Blood Adv. 2023 Aug 22;7(16):4647-4657. doi: 10.1182/bloodadvances.2023009729.
Blood Adv. 2023.
PMID: 37603347
Free PMC article.